Stephen Foley: GlaxoSmithKline case is a frightening reminder of why we need rules
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A decade ago, before everyone hated the banks, it was the pharmaceuticals industry which was Public Enemy No 1 – and the details revealed in GlaxoSmithKline's $3bn legal settlement in the US are a reminder of why.
Safety regulators are scrupulous about approving drugs to treat particular diseases for particular groups of people, and drug companies are banned from marketing the drugs for anything else and to anyone else, but time and again companies have been discovered making an end run round the regulations.
They have every incentive. Doctors are free to prescribe any drug for any condition if they believe it will help their patient, and in some blockbuster drugs this "off-label" use can account for one-quarter of all prescriptions or more.
For patients who get prescribed a new drug early, before regulators get round to sealing their approval, off-label use can be a huge boon. But cases like GSK's, where Paxil was later discovered to increase suicidal thoughts in children, are a reminder why we have scrupulous regulators. When drug companies break the rules, the potential consequences might be more frightening even than anything unleashed by the banks.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments